Investment Highlights for XBiotech Inc.

XBiotech addresses a growing market for targeted immunotherapies. By 2019, global sales of monoclonal antibodies (MAbs) are forecast to top $122 billion, up from $63 billion in 2013. Moreover, five of the 10 bestselling biotechnology drugs in the U.S. during 2013 were therapeutic MAbs, each with annual sales over $6 billion.

By using human-derived genes, True Human™ antibodies are not likely to be detected by the immune system as foreign, and thus, are expected to offer improved safety, efficacy, and commercial value versus existing antibody therapeutics, including those currently referred to as “fully human.”

XBiotech holds 39 issued and over 100 pending patent applications in various global jurisdictions. Its lead product candidate has intellectual property coverage in the U.S., Japan, Europe, and 14 other countries.

XBiotech has skilled leadership, including CEO John Simard, who was founder of CTL ImmunoTherapies and AlleCure, and a Board of Directors that includes the former CEO/chairman of Novartis, Dr. Vasella, who has been ranked among Europe’s and the world’s most influential leaders by both Time and the Financial Times; the former EVP of operations at Amgen, Dr. Bonanni; and Thorpe McKenzie, co-founder of Tiger Management (TIGER fund).

As of December 31, 2014, XBiotech reported cash of ~$57.3 million. The Company had raised over $130 million in private rounds and filed an S-1 registration statement with the SEC in Feb. 2015.